ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,863.70
0.63%
S&P ASX All Technology
3,056.60
0.37%
Brent Oil
83.515
-0.10%
US Dollar vs AUD
1.49365
0.08%
Bitcoin
67,050.07
1.34%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) News

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ASND
DateTimeSourceHeadlineSymbolCompany
17/05/202406:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
15/05/202404:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
15/05/202404:31GlobeNewswire Inc.Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
13/05/202422:30GlobeNewswire Inc.Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialNASDAQ:ASNDAscendis Pharma AS
09/05/202422:30GlobeNewswire Inc.Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024NASDAQ:ASNDAscendis Pharma AS
03/05/202406:01GlobeNewswire Inc.Ascendis Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
26/04/202406:46GlobeNewswire Inc.Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024NASDAQ:ASNDAscendis Pharma AS
24/04/202422:30GlobeNewswire Inc.United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
08/03/202403:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
06/03/202413:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
06/03/202400:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
06/03/202400:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
05/03/202423:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
05/03/202407:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
05/03/202407:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
05/03/202406:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
05/03/202406:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
05/03/202406:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
05/03/202400:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ASNDAscendis Pharma AS
02/03/202403:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
01/03/202409:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
29/02/202408:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
28/02/202409:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
22/02/202407:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
17/02/202409:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
17/02/202409:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
17/02/202409:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
15/02/202408:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
15/02/202403:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
15/02/202401:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Your Recent History

NYSE
ACDI
Ascendant Digital Acquis...
LATK
BCLUSDT
BITCOIN LEGEND
COIN
GPUUSD
LSE
CLBS
Celebrus Technologies
COIN
ODOGEUST
Ordinal Doge
USOTC
XNJJY
Goldwind Science and Tec... (PK)
NASDAQ
ARQ
Arq
EU
FR2CIBFS1126
Credit Agricole CIB FCIA...
TSX
5027
AnyMind
EU
BEC0000BIZD1
Crelan Floating Rate due...
ASX
NMINA
COIN
PENTGBP
Penchant Token
EU
AC
Accor
COIN
TVUSD
NASDAQ
HAMTOX
Hamilton Capital Targete...
USOTC
GLCP
Global Leaders (PK)
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved